List of works - Florian H Heidel

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

scientific article published on 04 November 2020

Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.

scientific article published on 23 February 2017

Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.

scientific article published on 18 July 2016

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

scientific article published on 05 June 2018

Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells

scientific article published on 06 August 2018

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

scholarly article by Francesca Palandri et al published November 2018 in Leukemia Research

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

scientific article

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients

scientific article published on 6 April 2018

Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging

scientific article published on 29 November 2018

Hacking the stem cell niche

scientific article published in June 2017

Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms

scientific article published in 2022

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

scientific article published on 07 June 2019

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

scientific article published on 04 December 2018

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

scientific article published on 20 December 2019

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments

scientific article published on 17 November 2020

Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells ⬇️

scientific article published on December 12, 2012

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

scientific article published in February 2018

Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders

scientific article published on 26 May 2020

RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA

scientific article published on 09 April 2020

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature ⬇️

scientific article published on June 11, 2013

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

scientific article published on 07 January 2021

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

scientific article published on 16 July 2018

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

scientific article published on 21 November 2020

Self-renewal related signaling in myeloid leukemia stem cells ⬇️

scientific article published on July 29, 2011

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms

scientific article published on 25 November 2020

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies ⬇️

scientific article published on March 9, 2012

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML ⬇️

scientific article published on December 31, 2012

List of works by Florian H Heidel